6/3/2014 9:59:34 AM
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Xcovery, a developer of next-generation targeted therapeutics for cancer, today presented preliminary results at the annual meeting of the American Society for Clinical Oncology (ASCO) from a phase 1 study of X-396, a potent small molecule anaplastic lymphoma kinase (ALK) inhibitor, that showed X-396 is well tolerated and has antitumor activity in patients with ALK positive non-small cell lung cancer (NSCLC).
Help employers find you! Check out all the jobs and post your resume.
comments powered by